Suven Life Sciences Ltd
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.[1]
- Market Cap ₹ 2,862 Cr.
- Current Price ₹ 132
- High / Low ₹ 169 / 78.1
- Stock P/E
- Book Value ₹ 37.9
- Dividend Yield 0.00 %
- ROCE -2.44 %
- ROE -2.36 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 3.47 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -47.2% over past five years.
- Company has a low return on equity of -4.52% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
258 | 510 | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 8 | |
205 | 291 | 361 | 369 | 378 | 392 | 237 | 48 | 44 | 48 | 41 | 43 | 48 | |
Operating Profit | 53 | 219 | 159 | 130 | 165 | 233 | 49 | -35 | -30 | -36 | -28 | -31 | -40 |
OPM % | 21% | 43% | 31% | 26% | 30% | 37% | 17% | -279% | -226% | -308% | -204% | -264% | -473% |
1 | 3 | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 18 | |
Interest | 14 | 11 | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 |
Depreciation | 8 | 9 | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 |
Profit before tax | 33 | 203 | 152 | 126 | 159 | 230 | 63 | -26 | -28 | -36 | -20 | -9 | -28 |
Tax % | 6% | 29% | 28% | 20% | 23% | 31% | 38% | -47% | -19% | 0% | 0% | -11% | |
31 | 144 | 109 | 100 | 123 | 158 | 39 | -14 | -23 | -36 | -20 | -8 | -27 | |
EPS in Rs | 1.76 | 8.23 | 5.70 | 5.24 | 6.47 | 8.30 | 2.05 | -0.72 | -1.19 | -1.66 | -0.92 | -0.37 | -1.22 |
Dividend Payout % | 11% | 20% | 7% | 25% | 10% | 12% | 49% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -31% |
5 Years: | -47% |
3 Years: | -5% |
TTM: | -32% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 4% |
TTM: | -62% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 47% |
3 Years: | 16% |
1 Year: | 67% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | -5% |
3 Years: | -5% |
Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 |
Reserves | 143 | 253 | 547 | 611 | 719 | 854 | 389 | 375 | 389 | 461 | 832 | 824 | 805 |
117 | 91 | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | |
56 | 132 | 105 | 68 | 74 | 114 | 35 | 16 | 9 | 7 | 5 | 5 | 10 | |
Total Liabilities | 328 | 487 | 773 | 774 | 876 | 1,014 | 439 | 410 | 415 | 486 | 860 | 851 | 837 |
162 | 179 | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 25 | |
CWIP | 4 | 13 | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 23 | 366 | 381 | 359 | 242 | 295 | 426 | 528 | 653 | 705 |
162 | 295 | 494 | 438 | 195 | 301 | 58 | 143 | 95 | 19 | 295 | 170 | 106 | |
Total Assets | 328 | 487 | 773 | 774 | 876 | 1,014 | 439 | 410 | 415 | 486 | 860 | 851 | 837 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | 121 | 143 | 90 | 147 | 105 | -12 | -45 | -37 | -37 | -23 | -21 | |
-15 | -36 | -110 | -62 | -353 | -38 | -4 | 42 | 2 | -107 | -349 | -1 | |
3 | -38 | 179 | -68 | -30 | -52 | 5 | 4 | 35 | 146 | 396 | -1 | |
Net Cash Flow | 19 | 47 | 212 | -40 | -236 | 15 | -11 | 1 | 1 | 2 | 24 | -22 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 34 | 47 | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 |
Inventory Days | 238 | 210 | 165 | 183 | 222 | 329 | 0 | |||||
Days Payable | 160 | 109 | 89 | 78 | 91 | 134 | ||||||
Cash Conversion Cycle | 112 | 148 | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 |
Working Capital Days | 50 | 62 | 69 | 77 | 66 | 103 | 56 | 1,211 | 1,320 | 331 | 470 | 397 |
ROCE % | 19% | 68% | 31% | 17% | 19% | 25% | 7% | -6% | -7% | -9% | -4% | -2% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Dec - Newspaper advertisement - communication to shareholders
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
8 Nov - Monitoring Agency Report on Rights Issue proceeds.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Oct - Copy of newspaper publication regarding financial results Q2 & half-year ended 30/09/2024
-
Statement Of Deviation(S) Or Variation(S) For Quarter Ended 30Th September, 2024 Under Regulation 32 Of SEBI (LODR) Regulations, 2015
29 Oct - Statement confirming no deviations in fund utilization.
- Outcome Of The Board Meeting - Financial Results For Quarter & Half-Year Ended 30/09/2024 29 Oct
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Concalls
-
Jul 2021TranscriptNotesPPT
-
Feb 2020TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
May 2019TranscriptNotesPPT
-
Feb 2019Transcript PPT
-
Feb 2019TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018Transcript PPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Jan 2018TranscriptNotesPPT
-
Dec 2017TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
May 2017Transcript PPT
-
Jan 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
Feb 2016TranscriptNotesPPT
Primary Focus
The company has been working towards developing new molecules/ compounds in the complex CNS (central nervous system) space. [1]
Most of its lead molecules address the niche areas of cognitive impairments such as amnesia, dementia, narcolepsy, Alzheimer's, delirium, etc. [2]
CNS is the 2nd largest therapeutic category in the pharmaceutical industry and is also one of the fastest growing segments. [3]